Estados financieros detallados de Dyne Therapeutics, Inc. (DYN): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | $1.37B | $506.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $2.28B | $2.93B | $24000 | $271000 | $700000 | 0 | 0 | $2.5M | $2.2M | $2.0M |
| Beneficio Bruto | -$915.0M | -$2.43B | -$24000 | -$271000 | -$700000 | 0 | 0 | -$2.5M | -$2.2M | -$2.0M |
| I+D | 0 | 0 | $4.3M | $11.0M | $45.2M | $121.3M | $142.8M | $210.8M | $281.4M | $398.3M |
| Generales y Administrativos | $161.0M | $189.0M | $517000 | $2.8M | $12.7M | $28.7M | $28.2M | $31.4M | $62.5M | $69.9M |
| Gastos Operativos | $161.0M | $189.0M | $4.8M | $13.8M | $57.9M | $150.0M | $171.0M | $239.7M | $341.6M | $466.1M |
| Beneficio Operativo | -$640.0M | -$412.0M | -$4.8M | -$13.8M | -$58.6M | -$150.0M | -$171.0M | -$242.2M | -$343.9M | -$468.2M |
| EBITDA | $106.0M | $949.0M | -$4.8M | -$14.6M | -$58.3M | -$148.2M | -$163.5M | -$233.5M | -$315.2M | -$438.0M |
| Gastos por Intereses | $625.0M | $616.0M | $5000 | 0 | $396000 | 0 | $2.9M | 0 | 0 | $6.2M |
| Beneficio Antes de Impuestos | -$1.29B | -$538.0M | -$4.8M | -$14.9M | -$59.4M | -$149.3M | -$168.1M | -$235.9M | -$317.4M | -$446.2M |
| Impuestos | -$45.0M | -$610.0M | -$11000 | 0 | -$700000 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$1.24B | $76.0M | -$4.8M | -$13.5M | -$58.7M | -$149.3M | -$168.1M | -$235.9M | -$317.4M | -$446.2M |
| BPA | $-9.61 | $0.47 | $-0.47 | $-0.30 | $-1.24 | $-2.93 | $-3.23 | $-3.95 | $-3.37 | $-3.47 |
| BPA Diluido | $-9.61 | $0.47 | $-0.47 | $-0.30 | $-1.24 | $-2.93 | $-3.23 | $-3.95 | $-3.37 | $-3.47 |
| Acciones en Circulación (Diluidas) | $129.0M | $162.0M | $10.3M | $45.4M | $47.3M | $50.9M | $52.0M | $59.7M | $94.1M | $128.4M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | -$521000 | 0 | 0 |
| Beneficio Operativo | -$113.9M | -$116.1M | -$125.3M | -$181.7M |
| EBITDA | -$104.6M | -$101.2M | -$116.1M | -$173.4M |
| Beneficio Neto | -$108.0M | -$112.0M | -$120.9M | -$178.6M |
| BPA | $-0.76 | $-0.76 | $-0.73 | $-1.08 |
| BPA Diluido | $-0.76 | $-0.76 | $-0.73 | $-1.08 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $1.78B | $365.0M | $8.1M | $14.6M | $300.9M | $200.8M | $172.1M | $121.6M | $435.4M | $893.4M |
| Inversiones a Corto | $130.0M | $32.0M | 0 | 0 | $44.5M | $175.7M | $83.9M | $1.5M | $206.8M | $217.2M |
| Cuentas por Cobrar | $386.0M | $513.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | $445.0M | $445.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $2.99B | $1.52B | $8.2M | $14.8M | $349.1M | $382.4M | $265.6M | $129.4M | $659.3M | $1.13B |
| Inmovilizado Material | $7.12B | $8.88B | $110000 | $1.5M | $1.9M | $41.0M | $38.4M | $33.4M | $30.0M | $44.8M |
| Fondo de Comercio | $799.0M | $772.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | $38.0M | $25.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $13.05B | $11.77B | $8.3M | $16.4M | $353.3M | $425.7M | $306.3M | $165.1M | $691.2M | $1.19B |
| Cuentas por Pagar | $332.0M | $367.0M | $518000 | $1.3M | $3.4M | $4.0M | $5.3M | $22.9M | $6.6M | $8.1M |
| Deuda a Corto | $201.0M | $105.0M | 0 | 0 | 0 | 0 | 0 | 0 | $4.8M | $5.0M |
| Pasivos Corrientes | $916.0M | $1.05B | $711000 | $2.4M | $11.0M | $28.7M | $28.1M | $51.1M | $42.3M | $50.6M |
| Deuda a Largo | $8.78B | $8.33B | $3.4M | 0 | 0 | 0 | 0 | 0 | 0 | $15.3M |
| Pasivos Totales | $11.01B | $9.87B | $13.1M | $2.4M | $11.0M | $57.5M | $54.0M | $73.8M | $61.4M | $214.8M |
| Reservas | -$1.93B | -$1.85B | -$4.9M | -$19.7M | -$79.2M | -$228.5M | -$396.6M | -$632.5M | -$949.9M | -$1.40B |
| Patrimonio Neto | $2.04B | $1.90B | -$4.9M | $14.0M | $342.4M | $368.2M | $252.4M | $91.3M | $629.8M | $972.1M |
| Deuda Total | $8.98B | $8.43B | $3.4M | 0 | 0 | $32.6M | $30.5M | $27.4M | $24.0M | $20.3M |
| Deuda Neta | $7.07B | $8.04B | -$4.7M | -$14.6M | -$345.3M | -$343.9M | -$225.5M | -$95.7M | -$618.3M | -$1.09B |
| Capital Circulante | $2.07B | $475.0M | $7.4M | $12.4M | $338.1M | $353.7M | $237.5M | $78.3M | $617.0M | $1.08B |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $573.6M | $893.4M | $753.1M | $676.1M |
| Activos Totales | $867.1M | $1.19B | $1.08B | $994.0M |
| Pasivos Totales | $175.3M | $214.8M | $214.9M | $291.9M |
| Patrimonio Neto | $691.8M | $972.1M | $865.1M | $702.2M |
| Deuda Total | $120.5M | $20.3M | $19.3M | $19.9M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$1.24B | $76.0M | -$4.8M | -$14.9M | -$59.4M | -$149.3M | -$168.1M | -$235.9M | -$317.4M | -$446.2M |
| Amortizaciones | $766.0M | $867.0M | $24000 | $271000 | $700000 | $1.1M | $1.7M | $1.7M | -$1.9M | $2.0M |
| Compensación en Acciones | 0 | 0 | $1000 | $26000 | $6.6M | $17.5M | $15.2M | $20.0M | $45.9M | $45.9M |
| Cambio en Capital Circulante | $938.0M | -$1.60B | $601000 | $1.4M | $5.1M | $9.3M | -$5.4M | $26.3M | -$19.5M | -$3.4M |
| Flujo de Caja Operativo | $676.0M | $585.0M | -$4.2M | -$11.8M | -$46.5M | -$119.6M | -$153.6M | -$188.2M | -$292.4M | -$403.2M |
| Inversiones (CapEx) | -$326.0M | -$224.0M | -$134000 | -$1.6M | -$1.2M | -$3.6M | -$3.1M | -$729000 | -$2.4M | -$1.9M |
| Adquisiciones | 0 | -$3.32B | 0 | 0 | 0 | $8000 | $34000 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | $350.0M | $361.0M | -$4.3M | -$13.5M | -$47.7M | -$123.2M | -$156.7M | -$188.9M | -$294.7M | -$405.1M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$90.8M | -$111.8M | -$144.9M | -$130.3M |
| Inversiones (CapEx) | -$19.2M | -$484000 | -$221000 | -$1.5M |
| Flujo de Caja Libre | -$110.0M | -$112.3M | -$145.1M | -$131.8M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | 0 | $11.2M | $13.1M | $15.0M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | -63.0% | -100.0% | | | | | | | |
| Crecimiento Beneficio Neto (anual) | | +106.1% | -106.3% | -181.4% | -333.9% | -154.2% | -12.6% | -40.4% | -34.5% | -40.6% |
| Crecimiento BPA (anual) | | +104.9% | -200.0% | +36.2% | -313.3% | -136.3% | -10.2% | -22.3% | +14.7% | -3.0% |
| Cambio en Acciones (anual) | | +25.6% | -93.6% | +339.9% | +4.1% | +7.7% | +2.1% | +14.8% | +57.7% | +36.4% |
| Crecimiento FCF (anual) | | +3.1% | -101.2% | -213.7% | -253.6% | -158.4% | -27.2% | -20.5% | -56.0% | -37.4% |
| Margen Bruto | -67.0% | -479.4% | | | | | | | | |
| Margen Operativo | -46.9% | -81.4% | | | | | | | | |
| Margen EBITDA | 7.8% | 187.5% | | | | | | | | |
| Margen Neto | -90.8% | 15.0% | | | | | | | | |
| Margen FCF | 25.6% | 71.3% | | | | | | | | |
| Tasa Impositiva Efectiva | 3.5% | 113.4% | 0.2% | -0.0% | 1.2% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $2.71 | $2.23 | $-0.42 | $-0.30 | $-1.01 | $-2.42 | $-3.02 | $-3.16 | $-3.13 | $-3.15 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $129.0M | $162.0M | $10.3M | $45.4M | $47.3M | $50.9M | $52.0M | $59.7M | $94.1M | $128.4M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.03 |
| Ratio corriente | 12.02 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -2.49 | 50.85 | -50.85 | -79.67 | -16.94 | -4.06 | -3.59 | -3.37 | -6.99 | -5.64 |
| P/VC | 1.51 | 2.04 | -50.58 | 77.34 | 2.90 | 1.64 | 2.39 | 8.70 | 3.52 | 2.58 |
| P/V | 2.26 | 7.65 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | -67.0% | -479.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | -46.9% | -81.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | -90.8% | 15.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |